Stock Price Quote

SMS PHARMACEUTICALS LTD.

NSE : SMSPHARMABSE : 532815ISIN CODE : INE812G01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE198.65-5.7 (-2.79 %)
PREV CLOSE ( ) 204.35
OPEN PRICE ( ) 209.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 20462
TODAY'S LOW / HIGH ( )196.25 209.05
52 WK LOW / HIGH ( )140.2 398
NSE198.54-6.39 (-3.12 %)
PREV CLOSE( ) 204.93
OPEN PRICE ( ) 205.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 94821
TODAY'S LOW / HIGH( ) 196.47 207.59
52 WK LOW / HIGH ( )141.25 398
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-12 1987
Management Info
Ramesh Babu Potluri - Chairman Ramesh Babu Potluri - Managing Director
Registered Office

Address Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. S B I Executive Enclave,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040 25259999

Email info@smspharma.com

Website www.smspharma.com

Registrars Details
Aarthi Consultants Pvt Ltd
1-2-285 ,Domalaguda,,Hyderabad
Listing : BSE, NSE

NEWS

28Dec Sms Pharmaceuticals informs about trad
Sms Pharmaceuticals has informed that the Trading Window for dealing in..
29Aug SMS Pharmaceuticals informs about comm
In compliance with the provisions of Regulation 30 of SEBI (Listing Obli..
12Jul SMS Pharmaceuticals informs about cert
In compliance with Regulation 74(5) of SEBI (Depositories and Participan..
21Mar SMS Pharmaceuticals informs about disc
SMS Pharmaceuticals has informed that the exchange has received the disc..
21Mar SMS Pharmaceuticals informs about disc
SMS Pharmaceuticals has informed that it enclosed the disclosure under R..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit171.72494.24
Gross Profit 225.32 663.31
Operating Profit 354.311213.04
Net Sales 1733.537092.63

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Ajanta Pharma (BSE)
peergroup  2558.40 (2.61%)
M.Cap ( in Cr)31957.51
Coral Laboratories (BSE)
peergroup  807.60 (8.54%)
M.Cap ( in Cr)288.52
Vimta Labs (BSE)
peergroup  1119.70 (3.91%)
M.Cap ( in Cr)2488.29
Mercury Laboratories (BSE)
peergroup  849.00 (3.78%)
M.Cap ( in Cr)101.88
Aarti Drugs (BSE)
peergroup  410.85 (7.20%)
M.Cap ( in Cr)3749.83

Shareholding Pattern

PROMOTERS 64.67%
NON-INSTITUTION 32.47%
MUTUAL FUNDS/UTI 2.55%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About SMS Pharmaceuticals Ltd.

SMS Pharmaceuticals Ltd. was incorporated in the year 1987. Its today's share price is 198.65. Its current market capitalisation stands at Rs 1681.61 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7510.07 Cr and Total Income of Rs.7137.23 Cr. The company's management includes Ramesh Babu Potluri , Ramesh Babu Potluri , Vamsi Krishna Potluri, Sarvepalli Srinivas, Neelaveni Thummala, Shravan Kudaravalli, Sarath Kumar Pakalapati, Thirumalesh Tumma.

It is listed on the BSE with a BSE Code of 532815 , NSE with an NSE Symbol of SMSPHARMA and ISIN of INE812G01025. It's Registered office is at Plot No. 72, H. No. 8-2-334 / 3 & 4,Road No. 5, Opp. S B I Executive Enclave,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are P Murali & Co, Rambabu & Co, Suryanarayana & Suresh

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.